Investor Market Move: Blue Jay Capital Management LLC Stake in Masimo Corp (MASI) Has Decreased by $3.12 Million as Market Valuation Rose

Investor Market Move: Blue Jay Capital Management LLC Stake in Masimo Corp (MASI) Has Decreased by $3.12 Million as Market Valuation Rose

Andrew Feldstein decreased its stake in Masimo Corp (MASI) by 24.13% based on its latest 2016Q3 regulatory filing with the SEC. Blue Jay Capital Management Llc sold 52,829 shares as the company’s stock rose 13.38% with the market. The hedge fund run by Andrew Feldstein held 166,131 shares of the electromedical & electrotherapeutic apparatus company at the end of 2016Q3, valued at $9.88M, down from 218,960 at the end of the previous reported quarter. Blue Jay Capital Management Llc who had been investing in Masimo Corp for a number of months, seems to be less bullish one the $3.59B market cap company. The stock is down 0.38% or $0.27 after the negative news, hitting $70.37 per share. About 171,318 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 36.98% since June 7, 2016 and is uptrending. It has outperformed by 29.56% the S&P500.

Blue Jay Capital Management Llc is a California-based hedge fund that was founded by Andrew Feldstein And Stephen Siderow. It had more than $137.80 million assets under management in May, 2014. Taken from Blue Jay Capital Management latest Adv, the fund reported to have 4 full and part-time employees. Among which 2 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Insitutional Activity: The institutional sentiment increased to 1.33 in Q3 2016. Its up 0.01, from 1.32 in 2016Q2. The ratio is positive, as 10 funds sold all MASI shares owned while 95 reduced positions. 47 funds bought stakes while 93 increased positions. They now own 39.80 million shares or 2.85% more from 38.69 million shares in 2016Q2. First Republic Inv holds 0.03% or 58,703 shares in its portfolio. Zacks Investment Mgmt holds 0.04% or 21,015 shares in its portfolio. Next Grp, a Texas-based fund reported 76 shares. Hussman Strategic Advisors has invested 1.96% of its portfolio in Masimo Corporation (NASDAQ:MASI). Nationwide Fund Advsrs holds 0.07% or 280,538 shares in its portfolio. Btim Corp holds 605,458 shares or 0.59% of its portfolio. Group Inc holds 30,902 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 1,348 shares. Ny State Teachers Retirement Sys has 96,956 shares for 0.02% of their US portfolio. Pacad Ltd has 5,653 shares for 0.04% of their US portfolio. Strs Ohio accumulated 22,100 shares or 0.01% of the stock. Dana Inv Advisors Incorporated, a Wisconsin-based fund reported 36,442 shares. Stevens Mngmt Limited Partnership has invested 0.05% of its portfolio in Masimo Corporation (NASDAQ:MASI). Blackrock Fund Advsr has 0.04% invested in the company for 3.08 million shares. Jane Street Gru Ltd accumulated 24,800 shares or 0.01% of the stock.

Insider Transactions: Since July 20, 2016, the stock had 0 insider purchases, and 32 selling transactions for $42.43 million net activity. Shares for $3.58M were sold by Sampath Anand on Monday, October 31. Jansen Paul also sold $141,548 worth of Masimo Corporation (NASDAQ:MASI) shares. FITCH SANFORD sold $118,102 worth of Masimo Corporation (NASDAQ:MASI) on Wednesday, October 19. McClenahan Thomas Samuel had sold 10,000 shares worth $660,000 on Friday, December 16. $268,798 worth of Masimo Corporation (NASDAQ:MASI) was sold by Van Ramshorst David J. Coleman Jon sold $360,000 worth of stock or 6,000 shares. Another trade for 104,870 shares valued at $6.53M was made by KIANI JOE E on Friday, November 25.

Analysts await Masimo Corporation (NASDAQ:MASI) to report earnings on February, 28. They expect $0.51 EPS, up 240.00% or $0.36 from last year’s $0.15 per share. MASI’s profit will be $26.02 million for 34.50 P/E if the $0.51 EPS becomes a reality. After $0.47 actual EPS reported by Masimo Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.

According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”

Masimo Corporation (NASDAQ:MASI) Ratings Coverage

Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Wednesday, August 5 the stock rating was maintained by TH Capital with “Buy”. The firm has “Outperform” rating given on Wednesday, January 6 by Raymond James.

MASI Company Profile

Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of